11C-methionine in the diagnostics and management of
glioblastoma patients with rapid early progression:
nonrandomized, open label, prospective clinical trial (GlioMET)

J 2024

11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)

LAKOMÝ, Radek, Martina LOJOVÁ, Lenka SOUČKOVÁ, Ludmila HYNKOVÁ, Kateřina POLÁCHOVÁ et. al.

Basic information

Original name

11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)

Authors

LAKOMÝ, Radek (203 Czech Republic, guarantor, belonging to the institution), Martina LOJOVÁ (203 Czech Republic, belonging to the institution), Lenka SOUČKOVÁ (203 Czech Republic, belonging to the institution), Ludmila HYNKOVÁ (203 Czech Republic, belonging to the institution), Kateřina POLÁCHOVÁ (203 Czech Republic, belonging to the institution), Jiri VASINA (203 Czech Republic), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Jiří ŠÁNA (203 Czech Republic, belonging to the institution), Tomáš PROCHÁZKA (203 Czech Republic, belonging to the institution), Martin SMRČKA (203 Czech Republic, belonging to the institution), Pavel FADRUS (203 Czech Republic, belonging to the institution), Radim JANČÁLEK (203 Czech Republic, belonging to the institution), Iveta SELINGEROVÁ (203 Czech Republic, belonging to the institution), Renata BELANOVA (203 Czech Republic), Pavel ŠLAMPA (203 Czech Republic, belonging to the institution), Petr POSPÍŠIL (203 Czech Republic, belonging to the institution) and Tomáš KAZDA (203 Czech Republic, belonging to the institution)

Edition

BMC Cancer, LONDON, BMC, 2024, 1471-2407

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

GliMet

Impact factor

Impact factor: 3.800 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s12885-024-12469-2

UT WoS

001249141700004

Keywords in English

Glioblastoma; Rapid early progression; Radiopharmaceutical; C-11-methionine; Clinical trial; Positron emission tomography; Radiotherapy

Abstract

V originále

Background Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If postoperative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is used for radiotherapy treatment planning. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery and is called rapid early progression (REP). Radiotherapy planning is currently based on MRI for target volumes definitions in many radiotherapy facilities. However, patients with REP may benefit from targeting radiotherapy with other imaging modalities. The purpose of the presented clinical trial is to evaluate the utility of C-11-methionine in optimizing radiotherapy for glioblastoma patients with REP. Methods This study is a nonrandomized, open-label, parallel-setting, prospective, monocentric clinical trial. The main aim of this study was to refine the diagnosis in patients with GBM with REP and to optimize subsequent radiotherapy planning. Glioblastoma patients who develop REP within approximately 6 weeks after surgery will undergo C-11-methionine positron emission tomography (PET/CT) examinations. Target volumes for radiotherapy are defined using both standard planning T1-weighted contrast-enhanced MRI and PET/CT. The primary outcome is progression-free survival defined using RANO criteria and compared to a historical cohort with REP treated without PET/CT optimization of radiotherapy. Discussion PET is one of the most modern methods of molecular imaging. C-11-Methionine is an example of a radiolabelled (carbon 11) amino acid commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. Optimized radiotherapy may also have the potential to cover those regions with a high risk of subsequent progression, which would not be identified using standard-of-care MRI for radiotherapy planning. This is one of the first study focused on radiotherapy optimization for subgroup of patinets with REP.

Links

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(CEP code: EF16_013/0001826)

Name: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií

Investor: Ministry of Education, Youth and Sports of the CR, Priority axis 1: Strengthening capacities for high-quality research

90249, large research infrastructures

Name: CZECRIN IV

Citovat

LAKOMÝ, Radek, Martina LOJOVÁ, Lenka SOUČKOVÁ, Ludmila HYNKOVÁ, Kateřina POLÁCHOVÁ, Jiri VASINA, Regina DEMLOVÁ, Alexandr POPRACH, Jiří ŠÁNA, Tomáš PROCHÁZKA, Martin SMRČKA, Pavel FADRUS, Radim JANČÁLEK, Iveta SELINGEROVÁ, Renata BELANOVA, Pavel ŠLAMPA, Petr POSPÍŠIL and Tomáš KAZDA. 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET). BMC Cancer. LONDON: BMC, 2024, vol. 24, No 1, p. 1-16. ISSN 1471-2407. Available from: https://dx.doi.org/10.1186/s12885-024-12469-2.

@article{2418638,
   author = {Lakomý, Radek and Lojová, Martina and Součková, Lenka and Hynková, Ludmila and Poláchová, Kateřina and Vasina, Jiri and Demlová, Regina and Poprach, Alexandr and Šána, Jiří and Procházka, Tomáš and Smrčka, Martin and Fadrus, Pavel and Jančálek, Radim and Selingerová, Iveta and Belanova, Renata and Šlampa, Pavel and Pospíšil, Petr and Kazda, Tomáš},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s12885-024-12469-2},
   keywords = {Glioblastoma; Rapid early progression; Radiopharmaceutical; C-11-methionine; Clinical trial; Positron emission tomography; Radiotherapy},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC Cancer},
   title = {11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)},
   url = {https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12469-2},
   volume = {24},
   year = {2024}
}

TY  - JOUR
ID  - 2418638
AU  - Lakomý, Radek - Lojová, Martina - Součková, Lenka - Hynková, Ludmila - Poláchová, Kateřina - Vasina, Jiri - Demlová, Regina - Poprach, Alexandr - Šána, Jiří - Procházka, Tomáš - Smrčka, Martin - Fadrus, Pavel - Jančálek, Radim - Selingerová, Iveta - Belanova, Renata - Šlampa, Pavel - Pospíšil, Petr - Kazda, Tomáš
PY  - 2024
TI  - 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)
JF  - BMC Cancer
VL  - 24
IS  - 1
SP  - 1-16
EP  - 1-16
PB  - BMC
SN  - 14712407
KW  - Glioblastoma
KW  - Rapid early progression
KW  - Radiopharmaceutical
KW  - C-11-methionine
KW  - Clinical trial
KW  - Positron emission tomography
KW  - Radiotherapy
UR  - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12469-2
N2  - Background Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If postoperative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is used for radiotherapy treatment planning. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery and is called rapid early progression (REP). Radiotherapy planning is currently based on MRI for target volumes definitions in many radiotherapy facilities. However, patients with REP may benefit from targeting radiotherapy with other imaging modalities. The purpose of the presented clinical trial is to evaluate the utility of C-11-methionine in optimizing radiotherapy for glioblastoma patients with REP. Methods This study is a nonrandomized, open-label, parallel-setting, prospective, monocentric clinical trial. The main aim of this study was to refine the diagnosis in patients with GBM with REP and to optimize subsequent radiotherapy planning. Glioblastoma patients who develop REP within approximately 6 weeks after surgery will undergo C-11-methionine positron emission tomography (PET/CT) examinations. Target volumes for radiotherapy are defined using both standard planning T1-weighted contrast-enhanced MRI and PET/CT. The primary outcome is progression-free survival defined using RANO criteria and compared to a historical cohort with REP treated without PET/CT optimization of radiotherapy. Discussion PET is one of the most modern methods of molecular imaging. C-11-Methionine is an example of a radiolabelled (carbon 11) amino acid commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. Optimized radiotherapy may also have the potential to cover those regions with a high risk of subsequent progression, which would not be identified using standard-of-care MRI for radiotherapy planning. This is one of the first study focused on radiotherapy optimization for subgroup of patinets with REP.
ER  -

LAKOMÝ, Radek, Martina LOJOVÁ, Lenka SOUČKOVÁ, Ludmila HYNKOVÁ, Kateřina POLÁCHOVÁ, Jiri VASINA, Regina DEMLOVÁ, Alexandr POPRACH, Jiří ŠÁNA, Tomáš PROCHÁZKA, Martin SMRČKA, Pavel FADRUS, Radim JANČÁLEK, Iveta SELINGEROVÁ, Renata BELANOVA, Pavel ŠLAMPA, Petr POSPÍŠIL and Tomáš KAZDA. 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET). \textit{BMC Cancer}. LONDON: BMC, 2024, vol.~24, No~1, p.~1-16. ISSN~1471-2407. Available from: https://dx.doi.org/10.1186/s12885-024-12469-2.

Detailed Information on Publication Record